University of New Mexico Hospital is Conducting a Study on the Effects of Bereavement and Depression

The study will be conducted as a 12 week, open-label trial, and will include seven one-hour appointments, with the first appointment lasting two hours.  Participants will be given Escitalopram (trade name Lexapro), which is a drug approved for treatment of depression.  The study will examine whether depression is suppressed with medication treatment, as well as if measures of grief improve.

           

The study is looking for 30 bereaved adults ages 18 and up, who suffer from depression brought on in the bereavement period following the loss of a parent, sibling, spouse/significant other, or child.  

 

            For more information please contact:  272-8288 or 272-4444.

 

Related Stories

Native Health

Native Health

Thirty-five million adults in the United States are affected by chronic kidney disease (CKD), including 17 percent of Native Americans in the Southwest.
A Triple Aim Best Practice

A Triple Aim Best Practice

The University of New Mexico Hospital’s Midwifery Practice has received a Triple Aim Best Practice recognition from the American College of Nurse Midwives.
Announcing the New Office of Professional Wellbeing

Announcing the New Office of Professional Wellbeing

As a means of supporting faculty and learners at the UNM School of Medicine in providing the highest quality medical care, the new Office of Professional Wellbeing (OPW) will provide initiatives that improve efficiency of practice, enhance a culture of wellness, and promote personal resiliency.